Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
Many professionals report awareness, but few actively prescribe the self-administered injectable contraceptive DMPA.
Datwyler says it has developed a first-to-market universal plunger for large-volume cartridges containing up to 20mL.
The collaboration between ten23 health and BD aims to commercialize the BD Libertas wearable injector for large-volume ...
Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and ...
The phase 3 IRAKLIA trial showed isatuximab's OBDS matches IV efficacy and pharmacokinetics, with fewer injection-site reactions. Subcutaneous isatuximab demonstrated a 71.1% objective response rate, ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
The Food and Drug Administration (FDA) has approved Zycubo® (copper histidinate) for the treatment of Menkes disease in pediatric patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results